<DOC>
	<DOCNO>NCT00091234</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know whether gemtuzumab ozogamicin effective standard supportive care treat old patient acute myeloid leukemia . PURPOSE : This randomized phase II/III trial study two different gemtuzumab ozogamicin regimen see well work compare standard supportive care treat old patient previously untreated acute myeloid leukemia .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare feasibility , toxicity , antileukemic activity two different dose regimen gemtuzumab ozogamicin ( GO ) vs standard supportive care old patient previously untreated acute myeloid leukemia candidate intensive chemotherapy . ( phase II ) - Compare efficacy toxicity best dose regimen GO select phase II v standard supportive care , term overall survival , patient . ( phase III ) OUTLINE : This randomize , open-label , multicenter phase II study follow phase III study . Patients stratify accord age ( 61 75 v 76 80 v 81 ) , CD33-positivity bone marrow blast ( &lt; 20 % vs 20-80 % v &gt; 80 % vs unknown ) , initial WBC hydroxyurea administration ( &lt; 30,000/mm^3 v ≥ 30,000/mm^3 ) , WHO performance status ( 0-1 v 2 v 3-4 ) , participate center . - Phase II : Patients randomize 1 3 treatment arm . - Arm I : Patients receive gemtuzumab ozogamicin ( GO ) IV 2 hour day 1 8 . Patients stable respond disease day 36 receive GO IV 2 hour every 4 week 8 course absence disease progression unacceptable toxicity . - Arm II : Patients receive GO IV 2 hour day 1 , 3 , 5 . Patients stable respond disease day 36 receive GO IV 2 hour every 4 week 8 course absence disease progression unacceptable toxicity . - Arm III : Patients receive standard supportive care . - Phase III : Patients randomize 1 2 treatment arm . - Arm I : Patients receive select treatment ( arm I arm II ) phase II . - Arm II : Patients receive standard supportive care . Patients receive GO treatment follow monthly 1 year every 3 month thereafter . Patients receive standard supportive care follow least every 4 week . PROJECTED ACCRUAL : A total 259 patient ( 75 phase II [ 25 per treatment arm ] 184 phase III [ 92 per treatment arm ] ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) At least 20 % bone marrow blast bone marrow aspiration biopsy All subtypes except M3 ( acute promyelocytic leukemia ) allow Previously untreated primary secondary disease ( include AML myelodysplastic syndrome ) Ineligible intensive chemotherapy , define 1 follow criterion : 61 75 year old AND WHO performance status &gt; 2 AND/OR unwilling receive intensive chemotherapy Over 75 year old No blast crisis chronic myeloid leukemia No AML supervention myeloproliferative disease WBC &lt; 30,000/mm^3 meet 1 follow criterion : WBC &lt; 30,000/mm^3 diagnosis AND prior treatment hydroxyurea WBC ≥ 30,000/mm^3 diagnosis AND receive mandatory pretreatment hydroxyurea ( 14 day duration ) WBC &lt; 30,000/mm^3 No active CNS leukemia PATIENT CHARACTERISTICS : Age See Disease Characteristics 61 Performance status See Disease Characteristics Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No arrhythmia require chronic treatment No congestive heart failure No symptomatic ischemic heart disease No severe cardiovascular disease Pulmonary No severe pulmonary dysfunction ≥ grade 3 Other No alcohol abuse No severe neurological psychiatric disease No active uncontrolled infection severe systemic infection No malignancy No psychological , familial , sociological , geographical condition would preclude study compliance followup HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent antiangiogenic drug Chemotherapy See Disease Characteristics Concurrent lowdose cytostatic agent ( i.e. , thioguanine mercaptopurine ) allow palliative care ( standard supportive care arm ) Endocrine therapy Prior corticosteroid ( duration ≤ 14 day ) primary secondary AML allow Radiotherapy Not specify Surgery Not specify Other No concurrent cytotoxic drug No concurrent experimental therapy No concurrent tyrosine kinase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>